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The eﬀects on the drug eﬄux of 3,3 ,4,4 ,5-pentachlorobiphenyl (PCB-126), the most toxic of all coplanar polychlorinated biphenyls
(Co-PCBs), were examined in KB-3 cells expressing human wild-type and mutant P-glycoprotein in which the 61st amino acid
was substituted for serine or phenylalanine (KB3-Phe61). In the cells expressing P-glycoproteins, accumulations of vinblastine and
colchicinedecreasedform85%to92%andfrom62%to91%,respectively,andthedrugtolerancesforthesechemicalswereincreased.
In KB3-Phe61, the decreases in drug accumulation were inhibited by adding PCB-126 in a way similar to that with cyclosporine A: by
adding 1µM PCB-126, the accumulations of vinblastine and colchicine increased up to 3.3- and 2.3-fold, respectively. It is suggested
that PCB-126 decreased the drug eﬄux by inhibiting the P-glycoprotein in KB3-Phe61. Since there were various P-glycoproteins and
many congeners of Co-PCBs, this inhibition has to be considered a new cause of the toxic eﬀects of Co-PCBs.
INTRODUCTION
Among the group of polychlorinated biphenyls
(PCBs),coplanarPCBs(Co-PCBs)areknowntobehighly
toxic and indestructible congeners [1, 2]. Co-PCBs had
been produced as useful artiﬁcial lubricants for the chem-
ical industry and in the manufacture of a variety of daily-
use products until their production and use were prohib-
ited. These chemicals have thoroughly polluted the envi-
ronment, and may have accumulated via the food chain
and bioaccumulation in humans and animals, especially
in their lipid-rich organs [2, 3, 4, 5]. In the environ-
ment, 3,3 ,4,4 ,5-pentachlorobiphenyl (PCB-126) which
is the most toxic congener of Co-PCBs is also highly
polluting the environment [1, 6]. Like dioxin, the mix-
ture of Co-PCBs or the metabolites of Co-PCBs seems to
produce either estrogenic or antiestrogenic eﬀects [7, 8].
Co-PCBs were the agonists for arylhydrocarbon receptors
(AhR) [1, 9], and they inhibited the estrogenic response
viacrosstalkbetweenAhRandestrogenreceptors[10,11].
Actually,Co-PCBshaveactedasenvironmentalendocrine
disruptors, exerting adverse biological eﬀects even at a
very low dose [6, 12]. They also disturbed normal fetal
andneonataldevelopment,producingmalformationsand
the onset of cancer [4, 6, 13, 14].
Drug transport systems such as P-glycoprotein are
present on the cell membrane to exclude toxic xenobi-
otics [15] and to transport metabolites such as steroid
hormones [16]. P-glycoprotein is capable of transporting
a variety of structurally unrelated chemicals [17]a n dc a n
induce multidrug resistance during cancer chemotherapy
[18,19].TheP-glycoprotein-mediatedtransportofchem-
icalswasinhibitedbyotherchemicals.CyclosporineA,for
example, competed with vinblastine for a site to bind to
P-glycoprotein, and inhibited the transport of this sub-
strate [20]. The most hydrophobic steroid hormone, pro-
gesterone, blocked vinblastine transport, although pro-
gesterone itself was not transported. In a series of steroid
hormones, it was revealed that the more hydrophobic the
congeners, the more potent their interference with the
transport of other chemicals [21]. One of the congeners
of Co-PCBs, 3,3 ,4,4 -tetrachlorobiphenyl (PCB-77), was
not transported by human P-glycoprotein, but accumu-
lated abundantly in cells as can be expected due to its
lipophilic nature [22]. Co-PCBs easily enter cells and may
accumulate in the cell membrane due to their lipophilic-
ity. P-glycoprotein in the cell membrane may be exposed
to Co-PCBs, which may modify the transport of other
drugs and metabolites in the same way as do hydrophobic
steroid hormones and cyclosporine A, thus altering the
eﬀects of those substances.138 Hiroshi Fujise et al 2004:3 (2004)
Table 1. Drug tolerance for vinblastine and colchicine in KB3-Vec and KB3-MDR1s, and the ratios for the tolerance of KB3-Vec to
KB3-MDR1s (KB3-MDR1s/KB3-Vec).
KB3-MDR1s
KB3-Vec KB3-His61 KB3-Phe61 KB3-Ser61
Vinblastine (ID50,n M ) 3.4 26 30 40
(KB3-MDR1s/KB3-Vec) (1) (7.6) (8.8) (11.8)
Colchicine (ID50,n M ) 8.8 46 859 43
(KB3-MDR1s/KB3-Vec) (1) (5.2) (97.6) (4.9)
Note. Inhibition dose for 50% cell growth (ID50) by adding chemicals was expressed as the index of drug tolerance.
Though P-glycoprotein has a low speciﬁcity for sub-
strates, it was found to contain many mutations of
amino acids that modulated substrate speciﬁcity [23, 24].
Such mutations might be involved in the modiﬁcation
of binding and transporting mechanisms. The toxic-
ity of drugs was reduced in the transformant cells ex-
pressing P-glycoprotein, probably due to an enhance-
ment of the drug eﬄux. These drug tolerances varied
among the transformant cells in which the His 61 po-
sition (His61) in the predicted transmembrane domain
1 of human P-glycoprotein was replaced with a variety
of amino acids [24]. Accordingly, the eﬀect of Co-PCBs
might diﬀer among the mutants of P-glycoproteins. The
possibility of a modiﬁcation in P-glycoprotein by bind-
ing with Co-PCBs must be examined. Here, we investi-
gated the eﬀect of PCB-126 on the eﬄux of vinblastine
and colchicine in KB-3 cells transfected with multidrug




For radioactive tracers, we used [G-3H]-vinblastine
sulphate (470GBq/mmol) (Amersham Pharmacia Bio-
tech, NJ, USA) and [3H]-colchicine (2,830GBq/mmol)
(Perkin Elmer Japan Co Ltd, Tokyo, Japan). As the rep-
resentative of Co-PCBs, PCB-126 (Kanto Kagaku, Tokyo,
Japan) was used, and cyclosporine A (Sigma, Mo, USA)
was used as the inhibitor of P-glycoprotein.
Cellculture
Thetransformantcellsofhumanculturedcells,thatis,
KB3-1 expressing with wild-type human P-glycoprotein
(KB3-His61) and the mutant P-glycoprotein, in which
His61 was substituted with serine (KB3-Ser61) or pheny-
lalanine (KB3-Phe61), were prepared as reported in [24].
As the control, KB3-1 transfected with the transfection
vector pHaMAIRESneo (KB3-Vec) was also used. These
cells were maintained in medium 199 supplemented with
1 0 %f e t a lc a l fs e r u m( F C S )i na na t m o s p h e r eo f5 %C O 2
at37◦C,andthetransformantcellsweremaintainedinthe
same medium with appropriate reagents; KB3-His61 and
KB3-Ser61 were maintained with 100µM vinblastine and
KB3-Phe61 with 60µM colchicine.
Drugtoleranceofcells
The cells were seeded in 96-well microplates at a den-
sity of 105/well in a 500-µL medium identical to that of
the maintenance culture except for varied concentrations
of vinblastine and colchicine, and then incubated for 4
days. The viability of these cells was then measured by
a colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (Wako Co Ltd, Osaka,
Japan). The inhibition dose for 50% cell growth (ID50)
was calculated as the index for drug tolerance.
Drugaccumulationanditsinhibition
For a determination of the cellular accumulation
of the chemicals, coverslips with a 24-well multidish
(Nalgen Nunc International, Ill, USA) were used. Cells
were seeded at a density of 5 × 106/well in a 750-µL
maintenance medium on the dish and incubated in 5%
CO2 at 37◦C. After 4 days, the medium was replaced
with a fresh medium without colchicine, and the cells
were incubated for 6hours. The medium was again re-
placed with a 750-µL fresh medium containing either
11nM [3H]-vinblastine (5.16kBq/mL) or 11nM [3H]-
colchicine (31.1kBq/mL). The coverslips were removed
from the 24-well dish after a 1-, 2-, and 3-hours incu-
bation. These cells were washed 3 times with PBS, and
treated with a lysing solution (cell culture lysis reagent,
Promega, Wis, USA) overnight. Radioactivity was then
measured by a liquid scintillation counter. The accumu-
lation was indicated as pmol/well.
To examine the eﬀect of PCB-126 on drug accumu-
lation, PCB-126 and the inhibitor of p-glycoprotein, cy-
closporine A, were added to the incubation medium. One
hundred pM to 10µM PCB-126 or cyclosporine A was
added to the medium, and the accumulations of vinblas-
tine and colchicine were measured.
Statistics
The student’s t-test was employed to examine the
statistical signiﬁcance of the accumulation between cell
groups.2004:3 (2004) PCB-126 Inhibits Drug Eﬄux Through P-Glycoprotein 139










































































































































Figure 1. (a) Uptake of vinblastine in KB3-1 expressing with
wild-type human P-glycoprotein (KB3-His61,ﬁ l l e dc i r c l e s ) ,m u -
tant P-glycoprotein in which His61 was replaced with pheny-
lalanine (KB3-Phe61, open squares) and serine (KB3-Ser61,
ﬁlled squares), and transfected with transfection vector (KB3-
Vec, open circles). (b) The ratios between the accumula-
tions of vinblastine with and without cyclosporine A (CYA)
and (c) PCB-126 (with/without CYA or PCB-126) in KB3-
Vec (open columns), KB3-His61 (cross-hatched columns), KB3-
Phe61 (hatched columns), and KB3-Ser61 (ﬁlled columns). ∗,
P<. 05 compared to KB3-Vec. Means and SD of 4 experiments.
RESULTS AND DISCUSSION
Table 1 indicatesthedrugtolerancesofKB3-Vec,KB3-
His61,KB3-Ser 61,andKB3-Phe 61 inthemediumwithvin-
blastine or colchicine. The ID50 increased in all the cell
groups expressing P-glycoprotein (KB3-MDR1s), KB3-
His61,K B 3 - S e r 61,a n dK B 3 - P h e 61,e x c e p tf o rK B 3 - V e c .A s











































































































































Figure 2. (a) Uptake of colchicine in KB3-1 expressing with
wild-type human P-glycoprotein (KB3-His61,ﬁ l l e dc i r c l e s ) ,m u -
tant P-glycoprotein in which His61 was replaced with pheny-
lalanine (KB3-Phe61, open squares) and serine (KB3-Ser61,
ﬁlled squares), and transfected with transfection vector (KB3-
Vec, open circles). (b) The ratios between the accumula-
tions of colchicine with and without cyclosporine A (CYA)
and (c) PCB-126 (with/without CYA or PCB-126) in KB3-
Vec (open columns), KB3-His61 (cross-hatched columns), KB3-
Phe61 (hatched columns), and KB3-Ser61 (ﬁlled columns). ∗,
P<. 05 compared to KB3-Vec. Means and SD of 4 experiments.
KB3-MDR1s except for KB3-Vec, and the order of drug
toleranceswasKB3-Ser61 >KB3-Phe61 >KB3-His61.W ith
colchicine, the ID50 increased around 5-fold in KB3-His61
and KB3-Ser61, and 98-fold in KB3-Phe61. The increase
in the ID50 for colchicine in KB3-Phe61 was extremely140 Hiroshi Fujise et al 2004:3 (2004)
high, indicating a special relation between the side chain
of Phe61 and the relatively smaller substrate, colchicine.
Taguchi et al showed an inverse relation between the bulk
of the side chain of the 61st amino acid in P-glycoprotein
and the molecular weight of the drug; the P-glycoprotein,
which has a large side chain in the 61st amino acid, in-
dicated less sensitivity to the smaller molecular weight of
the chemicals, and vice versa [24].
Figure 1a shows the vinblastine uptake as a func-
tion of time in KB3-Vec and of reductions in the up-
take in KB3-MDR1s. The uptakes of vinblastine in KB3-
Vec hyperbolically increased during a 3-hour incubation
as reported in [22], and the accumulations after that
incubation in KB3-His61,K B 3 - S e r 61,a n dK B 3 - P h e 61 were
reducedby85%,88%,and92%,respectively,comparedto
KB3-Vec. Thus, under such conditions, most of the drug
might have been transported to an extracellular site by
the P-glycoproteins which were expressed by transfection
with each MDR1 gene. These excretions might contribute
to the increase in ID50 in KB3-MDR1s.
Figures 1b and 1c show the eﬀects of cyclosporine A
(b) and PCB-126 (c) on the accumulations of vinblas-
tine after a 3-hours incubation in KB3-Vec and KB3-
MDR1s; the ratios between the accumulations with and
without cyclosporine A or PCB-126 in each cell group
were compared. An increase in the ratios indicates an in-
creased inhibition against the drug eﬄux due to the ad-
dition of cyclosporine A or PCB-126. The ratios were
increased by adding more than 1µM cyclosporine A in
all KB3-MDR1s, while there was no clear increase in the
ratio in KB3-Vec. The ratios in KB3-His61,K B 3 - S e r 61,
and KB3-Phe61 increased 7.0-, 6.3-, and 7.5-fold, respec-
tively, by adding 1µM cyclosporine A, and those accu-
mulations increased 9.2-, 9.1-, and 10.3-fold, respectively,
by adding 10µM cyclosporine A. Though the increase
in the ratio was less than 2-fold by adding 0.1µMc y -
closporine A, those in KB3-Phe61 and KB3-His61 were in-
creasedsigniﬁcantly.TheratioinKB3-Phe61 wasrelatively
higher than in the other cell groups, though the diﬀer-
ence among KB3-MDR1s was less than 20%. By adding
0.1, 1 and 10µM PCB-126, the ratio in KB3-Phe61 in-
creased1.4-,3.3-,and2.8-fold,respectively,thusrevealing
an inhibition of the drug eﬄux by the addition of PCB-
126. PCB-126 might have had an eﬀect on the mutant




Figure 2a shows the colchicine uptake as a function of
time in KB3-Vec and of reductions in the uptakes in KB3-
MDR1s. The colchicine uptake displayed a somewhat lin-
ear function compared to the vinblastine uptake in all cell
groups. The accumulations after a 3-hours incubation in
KB3-His61,K B 3 - S e r 61,a n dK B 3 - P h e 61 were reduced, re-
spectively, by 75, 62, and 91% compared to that in KB3-
Vec. Thus, under those conditions, KB3-Phe61 demon-
strated the highest ability to transport colchicine, while
KB3-Ser61 showed the lowest.
Figures 2b and 2c show the eﬀects of cyclosporine
A (b) and PCB-126 (c) on the accumulations during a
3-hours incubation in KB3-Vec and KB3-MDR1s. The
ratios between accumulations with and without these
chemicals in KB3-His61,K B 3 - S e r 61,a n dK B 3 - P h e 61 in-
creased 2.6-, 2.0-, and 5.8-fold by adding 1µMc y -
closporine A, and increased 3.6-, 2.9-, and 9.2-fold by
adding 10µM cyclosporine A, respectively, while there
w a sn os u c he ﬀect in KB3-Vec. The cell group which
showed the largest reduction in drug accumulation, KB3-
Phe61, also showed the largest increase in accumulation
when the inhibitor for P-glycoprotein was added. This
might be due to an inhibition of the eﬄux through P-
glycoprotein as reported in [21]. These eﬀects of cy-
closporine A on drug accumulation were considered
due to a modiﬁcation of P-glycoprotein by its bind-
ing [20]. By adding 1 and 10µM PCB-126, the ra-
tios in KB3-Phe61 increased 2.3- and 2.1-fold, respec-
tively, indicating an inhibition of the drug eﬄux. The
ratios in KB3-His61 and KB3-Ser61 increased slightly,
though there was no signiﬁcant diﬀerence from that
in KB3-Vec. Thus, PCB-126 might have bound with
Phe61 mutant P-glycoprotein to inhibit the eﬄux of
colchicine.
In all KB3-MDR1s, accumulations of vinblastine were
equally reduced, and cyclosporine A inhibited these re-
ductions to almost the same degree among KB3-MDR1s.
However, the reductions and inhibitions in the accumula-
tion of colchicine varied among cell groups. Previously,
one of the present authors revealed that the cells ex-
pressing mutant P-glycoprotein which possessed a larger
61st amino acid gained a tolerance to various chemicals,
whereas, in the cells expressing the mutant P-glycoprotein
which possessed a smaller 61st amino acid, the toler-
ance for large chemicals was superior to that for small
chemicals [24]. These results were explained as being
due to the diﬀerence in the bulk of the side chain of
the 61st amino acid in P-glycoprotein, rather than to
the electron charge or hydrophilicity in the side chain.
In this experiment, KB3-Phe61 showed a superior abil-
ity for excretion in both vinblastine and colchicine, and
the excretion in KB3-Phe61 was more potently inhib-
ited by cyclosporine A and PCB-126 compared to the
other cells. These results showed that the Phe61 mutant
P-glycoprotein in which the side chain of the 61st amino
acid was larger than that in the other mutants was less
speciﬁc for substrates. Therefore, it might have reacted
to a variety of substrates with almost the same aﬃnity.
However, the wild type, His61 P-glycoprotein, and Ser61
mutant P-glycoprotein were somewhat speciﬁc for sub-
strates, and their aﬃnity was predominant in the larger
substrate, vinblastine. The Phe61 mutant P-glycoprotein
might have the ability to bind with a variety of chemi-
cals dissimilar to one another in structure and molecu-
lar size. Thus, PCB-126 might also bind to the Phe61 mu-
tant P-glycoprotein and inhibit the eﬄux of vinblastine
and colchicine, while being unable to react with the other
P-glycoproteins.2004:3 (2004) PCB-126 Inhibits Drug Eﬄux Through P-Glycoprotein 141
The contamination level of Co-PCBs and the concen-
trations used in this experiment will now be discussed.
As a result of their locations on the food chain, sev-
eral marine mammals showed high levels of contamina-
tion with PCBs, that is, up to around 5mg/kg in their
blubber [25]. In humans who consumed high levels of
ﬁsh, the total content of lipid-adjusted plasma PCBs in-
creased up to 770µg/kg [26], and PCB-126 accumulated
up to 1.4µg/kg in plasma lipid [4]. Among workers em-
ployed in capacitor manufacturing, the concentrations
of high- and low-chlorinated PCBs in adipose tissue in-
creased up to 165 and 414µg/kg, respectively [27]. PCBs
are highly lipophilic and may accumulate in the lipid bi-
layers of the cell membrane. In the present experiment,
theeﬀectofCo-PCBswasrevealedatlevelsof0.1to10µM
PCB-126, that is, 30 to 3000µg/kg of PCB-126. There-
fore, in populations exposed to an environment highly
contaminated with PCBs, the concentrations of PCBs or
Co-PCBs in their cell membranes would probably in-
crease to around the concentrations found in this experi-
ment.
In conclusion, it was indicated that PCB-126 inhib-
ited the drug eﬄux through the mutant P-glycoprotein
in KB3-Phe61. The interaction of PCB-126 with P-
glycoprotein was modiﬁed by the mutation of the 61st
amino acid of the protein. There have been many
amino acid mutations that modulated substrate speci-
ﬁ c i t yi nP - g l y c o p r o t e i n[ 28]. Therefore, there may be
P-glycoproteins which are aﬀected by some congener(s)
of Co-PCBs as revealed in this experiment. Though
the precise mechanism of toxicity is still unknown, P-
glycoprotein plays a role both in the extrusion of xeno-
biotics and in the transport of steroid hormones [16, 21].
Consequently, not only the toxicities of xenobiotics but
also the eﬀects of steroid hormones may be disturbed
by Co-PCBs. In particular, the regulation of brain dif-
ferentiation in an embryo by steroid hormones seems to
be inﬂuenced by Co-PCBs. In addition to the reported
mechanism for toxicities [1, 7, 8, 9, 10, 11, 12], the ef-
fect of Co-PCBs on P-glycoprotein has to be consid-
ered as a new cause of the toxic eﬀects of these chemi-
cals.
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